# Vertex Pharmaceuticals (VRTX) EPS: $15.32 in 2025

URL: https://funkfolio.com/stock/VRTX/eps

> Vertex Pharmaceuticals (VRTX) earnings per share (EPS) was $15.32 in fiscal 2025. Over five fiscal years it grew 8.3% a year.

---

## Vertex Pharmaceuticals (VRTX) earnings per share (EPS)

**Earnings per share · fiscal 2025:** $15.32 year ended Dec 31, 2025

Vertex Pharmaceuticals (VRTX) reported diluted earnings per share of $15.32 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$2.08. Figures as of 17 Nov 2026, 22:35 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Earnings per share, fiscal 2025:** $15.32
- **Growth, 5 years:** +8.3% a year
- **Highest on record:** $15.32 fiscal 2025
- **Lowest on record:** -$3.77 fiscal 2010
- **Fiscal years on record:** 18 2008–2025

Figures as of 17 Nov 2026, 22:35 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Vertex Pharmaceuticals earnings per share (EPS), in more detail

Over the five fiscal years to 2025 diluted earnings per share grew at a compound 8.3% a year. Across the 18 fiscal years on record (2008–2025), the highest was $15.32 in fiscal 2025 and the lowest -$3.77 in fiscal 2010.

### Earnings per share by fiscal year

### Vertex Pharmaceuticals earnings per share (EPS), year by year

Vertex Pharmaceuticals (VRTX) earnings per share (EPS) by fiscal year

| Fiscal year | Earnings per share | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $15.32 | — | Dec 31, 2025 |
| 2024 | -$2.08 | 115.0% down | Dec 31, 2024 |
| 2023 | $13.89 | 8.3% up | Dec 31, 2023 |
| 2022 | $12.82 | 42.3% up | Dec 31, 2022 |
| 2021 | $9.01 | 12.4% down | Dec 31, 2021 |
| 2020 | $10.29 | 128.2% up | Dec 31, 2020 |
| 2019 | $4.51 | 44.3% down | Dec 31, 2019 |
| 2018 | $8.09 | 677.9% up | Dec 31, 2018 |
| 2017 | $1.04 | — | Dec 31, 2017 |
| 2016 | -$0.46 | — | Dec 31, 2016 |
| 2015 | -$2.31 | — | Dec 31, 2015 |
| 2014 | -$3.14 | — | Dec 31, 2014 |
| 2013 | -$1.98 | — | Dec 31, 2013 |
| 2012 | -$0.50 | 457.1% down | Dec 31, 2012 |
| 2011 | $0.14 | — | Dec 31, 2011 |
| 2010 | -$3.77 | — | Dec 31, 2010 |
| 2009 | -$3.71 | — | Dec 31, 2009 |
| 2008 | -$3.27 | — | Dec 31, 2008 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

### How to read it

It shows how much profit stands behind each share, so it rises when profit grows or when buybacks shrink the share count.

### Earnings per share at health care companies of similar size

Earnings per share of Vertex Pharmaceuticals and comparable companies

| Company | Earnings per share | Fiscal year |
| --- | --- | --- |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/eps) | $1.36 | 2025 |
| [Danaher DHR](https://funkfolio.com/stock/DHR/eps) | $5.05 | 2025 |
| [Intuitive Surgical ISRG](https://funkfolio.com/stock/ISRG/eps) | $7.87 | 2025 |
| Vertex Pharmaceuticals VRTX | $15.32 | 2025 |
| [Medtronic MDT](https://funkfolio.com/stock/MDT/eps) | $3.73 | 2026 |
| [Bristol-Myers Squibb BMY](https://funkfolio.com/stock/BMY/eps) | $3.46 | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Vertex Pharmaceuticals, figure by figure

- [Vertex Pharmaceuticals market cap](https://funkfolio.com/stock/VRTX/market-cap)
- [Vertex Pharmaceuticals revenue](https://funkfolio.com/stock/VRTX/revenue)
- [Vertex Pharmaceuticals earnings](https://funkfolio.com/stock/VRTX/earnings)
- [Vertex Pharmaceuticals P/E ratio](https://funkfolio.com/stock/VRTX/pe-ratio)
- [Vertex Pharmaceuticals P/S ratio](https://funkfolio.com/stock/VRTX/ps-ratio)
- [Vertex Pharmaceuticals P/B ratio](https://funkfolio.com/stock/VRTX/pb-ratio)
- [Vertex Pharmaceuticals free cash flow](https://funkfolio.com/stock/VRTX/free-cash-flow)
- [Vertex Pharmaceuticals operating margin](https://funkfolio.com/stock/VRTX/operating-margin)
- [Vertex Pharmaceuticals dividend](https://funkfolio.com/stock/VRTX/dividend)
- [Vertex Pharmaceuticals shares outstanding](https://funkfolio.com/stock/VRTX/shares-outstanding)
- [Vertex Pharmaceuticals total debt](https://funkfolio.com/stock/VRTX/total-debt)
- [Vertex Pharmaceuticals cash on hand](https://funkfolio.com/stock/VRTX/cash)
- [Vertex Pharmaceuticals total assets](https://funkfolio.com/stock/VRTX/total-assets)
- [Vertex Pharmaceuticals return on equity (ROE)](https://funkfolio.com/stock/VRTX/roe)
- [Vertex Pharmaceuticals return on invested capital (ROIC)](https://funkfolio.com/stock/VRTX/roic)

[Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecard](https://funkfolio.com/stock/VRTX) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Vertex Pharmaceuticals earnings per share (EPS): questions and answers

**What is Vertex Pharmaceuticals's diluted earnings per share?**

Vertex Pharmaceuticals (VRTX) reported diluted earnings per share of $15.32 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$2.08.

**What is the growth rate of Vertex Pharmaceuticals's diluted earnings per share?**

Over the five fiscal years to 2025 diluted earnings per share grew at a compound 8.3% a year.

**What are the highest and lowest diluted earnings per share figures on record for Vertex Pharmaceuticals?**

Across the 18 fiscal years on record (2008–2025), the highest was $15.32 in fiscal 2025 and the lowest -$3.77 in fiscal 2010.

**How is Vertex Pharmaceuticals's diluted earnings per share calculated?**

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

Fiscal years are named for the calendar year they end in.

### Learn: earnings per share (EPS)

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Revenue vs earnings vs free cash flow: what each tells you](https://funkfolio.com/learn/stocks/revenue-earnings-free-cash-flow)

  Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- [P/E ratio explained: what a high or low figure means](https://funkfolio.com/learn/stocks/pe-ratio)

  The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.

### Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) earnings per share (EPS)”, data as of 17 November 2026. https://funkfolio.com/stock/VRTX/eps

Underlying data: the company's filings with the SEC and Yahoo Finance.
